StocksMedium•10 November 2026•
1 min read
Upstream Bio Reports Wider-Than-Expected Q3 Loss
Key Facts
1Upstream Bio reported a quarterly loss of $0.75 per share, wider than the Zacks Consensus Estimate of a $0.67 loss.
2The company's losses widened compared to a year ago when it reported a loss of $0.63 per share.
Upstream Bio reported a quarterly loss of $0.75 per share for the third quarter of 2026. Zacks reported that the results were wider than the consensus estimate of a $0.67 loss per share, missing analyst expectations for the period.
The company's losses widened compared to the same quarter last year, when it reported a loss of $0.63 per share. In the equity market, UPB closed at $3.58 on November 9, 2026, after trading between a low of $3.17 and a high of $3.6 during the session.